Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00649155 | Fasting Study of Ciprofloxacin Extended-Release Tablets 500 mg and Cipro® XR Tablets 500 mg | PHASE1 | COMPLETED | 36 | — | — | Nov 1, 2005 | Nov 1, 2005 | Apr 24, 2024 | 1 | United States |
| NCT00649662 | Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg | PHASE1 | COMPLETED | 36 | — | — | Oct 1, 2005 | Oct 1, 2005 | Apr 24, 2024 | 1 | United States |
| NCT00650351 | Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg | PHASE1 | COMPLETED | 35 | — | — | Oct 1, 2005 | Oct 1, 2005 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Ciprofloxacin Extended-Release Tablets 500 mg |
| 2 | ACTIVE_COMPARATOR | Cipro® XR Tablets 500 mg |
| Name | Type | Description |
|---|---|---|
| Ciprofloxacin Extended-Release Tablets 500 mg | DRUG | 500mg, single dose fasting |
| Cipro® XR Tablets (500 mg | DRUG | 500mg, single dose fasting |
| Ciprofloxacin Extended-Release Tablets 1000 mg | DRUG | 1000mg, single dose fasting |
| Cipro® XR Tablets 1000 mg | DRUG | 1000mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (β-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the eveni...